Literature DB >> 11786517

Vascular origin of a soluble truncated form of the hepatocyte growth factor receptor (c-met).

Nadeem Wajih1, Jennifer Walter, David C Sane.   

Abstract

Hepatocyte growth factor (scatter factor) is an angiogenic growth factor that binds to its cellular transmembrane receptor, c-met. Both HGF and c-met are expressed by vascular smooth muscle and endothelial cells, where HGF may exert autocrine and paracrine effects. We have found that human aortic smooth muscle cells (HASMCs) and human umbilical vein endothelial cells (HUVECs) release a soluble, truncated form of c-met. Receptor shedding was induced by treatment of the cells with phorbol 12-myristate 13-acetate (PMA) and by the ligand, HGF. Shedding was inhibited by cycloheximide, a metalloproteinase inhibitor, and protein kinase C inhibitors. The soluble form of c-met was able to bind HGF, although with reduced affinity (K(d) approximately 10 nmol/L) compared with the membrane bound receptor. Conditioned medium containing soluble c-met inhibited the induction of Akt phosphorylation by HGF in HUVECs. The soluble truncated form of c-met was detectable in the plasma of 5 healthy volunteers. The shedding of c-met may represent a novel mechanism for regulating the mitogenic, motogenic, and morphogenic effects of hepatocyte growth factor.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11786517     DOI: 10.1161/hh0102.102756

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  13 in total

1.  Down-regulation of the met receptor tyrosine kinase by presenilin-dependent regulated intramembrane proteolysis.

Authors:  Bénédicte Foveau; Frédéric Ancot; Catherine Leroy; Annalisa Petrelli; Karina Reiss; Valérie Vingtdeux; Silvia Giordano; Véronique Fafeur; David Tulasne
Journal:  Mol Biol Cell       Date:  2009-03-18       Impact factor: 4.138

Review 2.  MET signalling: principles and functions in development, organ regeneration and cancer.

Authors:  Livio Trusolino; Andrea Bertotti; Paolo M Comoglio
Journal:  Nat Rev Mol Cell Biol       Date:  2010-12       Impact factor: 94.444

3.  Cross talk between c-Met and epidermal growth factor receptor during retinal pigment epithelial wound healing.

Authors:  Ke-Ping Xu; Fu-Shin X Yu
Journal:  Invest Ophthalmol Vis Sci       Date:  2007-05       Impact factor: 4.799

4.  Regulated proteolytic processing of Tie1 modulates ligand responsiveness of the receptor-tyrosine kinase Tie2.

Authors:  Marie B Marron; Harprit Singh; Tariq A Tahir; Jais Kavumkal; Hak-Zoo Kim; Gou Young Koh; Nicholas P J Brindle
Journal:  J Biol Chem       Date:  2007-08-29       Impact factor: 5.157

Review 5.  Physiological Signaling and Structure of the HGF Receptor MET.

Authors:  Gianluca Baldanzi; Andrea Graziani
Journal:  Biomedicines       Date:  2014-12-31

6.  Clinical value of CagA, c-Met, PI3K and Beclin-1 expressed in gastric cancer and their association with prognosis.

Authors:  Xiaojun Huang; Chaoqun Wang; Jinmin Sun; Jun Luo; Jiangzhou You; Linchuan Liao; Mingyuan Li
Journal:  Oncol Lett       Date:  2017-11-13       Impact factor: 2.967

Review 7.  c-Met expression and activity in urogenital cancers - novel aspects of signal transduction and medical implications.

Authors:  Ralf Hass; Susanne Jennek; Yuanyuan Yang; Karlheinz Friedrich
Journal:  Cell Commun Signal       Date:  2017-02-17       Impact factor: 5.712

8.  Targeting the degradation of AXL receptor tyrosine kinase to overcome resistance in gefitinib-resistant non-small cell lung cancer.

Authors:  Song Yi Bae; Ji-Young Hong; Hye-Jung Lee; Hyen Joo Park; Sang Kook Lee
Journal:  Oncotarget       Date:  2015-04-30

9.  Investigating the Relationship between Serum Level of s-Met (Soluble Hepatic Growth Factor Receptor) and Preeclampsia in the First and Second Trimesters of Pregnancy.

Authors:  Farshad Naghshvar; Zhila Torabizadeh; Narges Moslemi Zadeh; Hooman Mirbaha; Parand Gheshlaghi
Journal:  ISRN Obstet Gynecol       Date:  2013-07-31

10.  Plasma dynamic monitoring of soluble c-Met level for EGFR-TKI treatment in advanced non-small cell lung cancer.

Authors:  Hong-Fei Gao; Jin-Ji Yang; Zhi-Hong Chen; Xu-Chao Zhang; Hong-Hong Yan; Wei-Bang Guo; Qing Zhou; Lou-Ying Gou; Zhong-Yi Dong; Yi-Long Wu
Journal:  Oncotarget       Date:  2016-06-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.